Literature DB >> 15726906

Potentials of magnesium treatment in subarachnoid haemorrhage.

W M van den Bergh1, R M Dijkhuizen, G J E Rinkel.   

Abstract

Subarachnoid hemorrhage from a ruptured aneurysm is a subset of stroke. The young age (median 55 years) and poor outcome (50% of patients die; 30% of survivors remain dependent) explain why in the population the loss of productive life years from aneurysmal subarachnoid hemorrhage (SAH) is as large as that from brain infarcts, the most common type of stroke. Ischemia plays an important role in the pathophysiological process after SAH. A period of global cerebral ischemia firstly occurs in the acute phase, immediately after rupture of the aneurysm, due to acute vasoconstriction and elevated intracranial pressure, which leads to a drop in perfusion pressure. This is quite distinct from the secondly, delayed cerebral ischemia (DCI), which is focal or multi-focal. DCI usually occurs between 4 and 10 days after the initial bleeding, has a gradual onset and is multi-focal, and is an important cause of death and dependency after SAH. The interval between the bleeding and the onset of ischemia provides an opportunity for preventive treatment. Magnesium is readily available, inexpensive and has a well-established clinical profile in obstetrical and cardiovascular practice. It is beneficial in the treatment of eclampsia, a disease with a pathophysiology comparable to DCI after subarachnoid hemorrhage. Neuroprotective mechanisms of magnesium include inhibition of the release of excitatory amino-acids and blockade of the NMDA-glutamate receptor. Magnesium is also a non-competitive antagonist of voltage dependent calcium channels, has cerebrovascular dilatory activity and is an important co-factor of cellular ATPases, including the Na/K-ATPase. Magnesium can reverse delayed cerebral vasospasm and reduces the extent of acute ischemic cerebral lesions after experimental subarachnoid hemorrhage in rats. In this article we discuss the neuroprotective potency of magnesium in SAH by describing the pathophysiology of ischaemia after SAH and the many ways magnesium may interfere with this.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15726906

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  18 in total

Review 1.  Magnesium sulfate administration in subarachnoid hemorrhage.

Authors:  Jose I Suarez
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

2.  Controversies and evolving new mechanisms in subarachnoid hemorrhage.

Authors:  Sheng Chen; Hua Feng; Prativa Sherchan; Damon Klebe; Gang Zhao; Xiaochuan Sun; Jianmin Zhang; Jiping Tang; John H Zhang
Journal:  Prog Neurobiol       Date:  2013-09-25       Impact factor: 11.685

Review 3.  The importance of early brain injury after subarachnoid hemorrhage.

Authors:  Fatima A Sehba; Jack Hou; Ryszard M Pluta; John H Zhang
Journal:  Prog Neurobiol       Date:  2012-03-10       Impact factor: 11.685

4.  Cerebral Vasospasm in Critically III Patients with Aneurysmal Subarachnoid Hemorrhage: Does the Evidence Support the Ever-Growing List of Potential Pharmacotherapy Interventions?

Authors:  Tyree H Kiser
Journal:  Hosp Pharm       Date:  2014-11

5.  Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage.

Authors:  Walter M van den Bergh; Jolanda M W van de Water; Reinier G Hoff; Ale Algra; Gabriel J E Rinkel
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 6.  Calcium antagonists for aneurysmal subarachnoid haemorrhage.

Authors:  S M Dorhout Mees; G J E Rinkel; V L Feigin; A Algra; W M van den Bergh; M Vermeulen; J van Gijn
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

7.  Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat.

Authors:  Kentaro Mori; Masahiro Miyazaki; Junko Iwata; Takuji Yamamoto; Yasuaki Nakao
Journal:  Neurosurg Rev       Date:  2008-02-06       Impact factor: 3.042

8.  Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial.

Authors:  Sanne M Dorhout Mees; Ale Algra; W Peter Vandertop; Fop van Kooten; Hans A J M Kuijsten; Jelis Boiten; Robert J van Oostenbrugge; Rustam Al-Shahi Salman; Pablo M Lavados; Gabriel J E Rinkel; Walter M van den Bergh
Journal:  Lancet       Date:  2012-05-25       Impact factor: 79.321

9.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31

10.  Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Josef Flammer
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.